Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Assets (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Non-Current Assets for 2 consecutive years, with $35.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 10.09% to $35.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $148.9 million through Dec 2025, down 9.05% year-over-year, with the annual reading at $35.6 million for FY2025, 10.09% down from the prior year.
  • Non-Current Assets hit $35.6 million in Q4 2025 for Prelude Therapeutics, down from $36.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $41.7 million in Q1 2024 to a low of $35.6 million in Q4 2025.